GlaxoSmithKline Consumer Healthcare has announced the approval of Flonase Allergy Relief fluticasone propionate nasal spray for the treatment of allergic rhinitis for over-the-counter (OTC) sales in Canada. The nasal spray will be available OTC for patients 18 years old and over beginning in early 2017.
GSK President of Consumer Healthcare North America Colin Mackenzie commented, “With the significant number of allergy sufferers in Canada and a considerable number of those unsatisfied with their current treatments, we believe the wide availability of Flonase Allergy Relief over-the-counter is great news for these individuals. GSK has a strong heritage—40+years— in discovering and developing respiratory products used by patients worldwide. We are proud of our track record of successful Rx-to-OTC switches which over the years have significantly improved access to important medicines for our consumers.”
Flonase has been available over the counter for adults in the US since February 2015 and for children in the US since March 2016.
Read the GSK press release.
